New treatment approaches in renal cell carcinoma

Anti-Cancer Drugs

Volumn 20, Issue 10, 2009, Pages 893-900

  Facchini, Gaetano ^a   Perri, Francesco ^a   Caraglia, Michele ^b   Pisano, Carmela ^a   Striano, Stefano ^a   Marra, Luigi ^a   Fiore, Francesco ^a   Aprea, Pasquale ^a   Pignata, Sandro ^a   Iaffaioli, Rosario Vincenzo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bevacizumab; Everolimus; Interferon a; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapies

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ENDOTHELIAL CELL GROWTH FACTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANEMIA; ANGIOGENESIS; BIRT HOGG DUBE SYNDROME; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CLINICAL ASSESSMENT; DIARRHEA; DRUG INDICATION; FAMILIAL CANCER; FATIGUE; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEIOMYOMATOSIS; METASTASIS; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SKIN TOXICITY; STOMATITIS; VON HIPPEL LINDAU DISEASE;

BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, RENAL CELL; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73349131053     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833123d4     Document Type: Review

References (59)

1. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24:5601-5608.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-875.
3. Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-2867.
4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 1999; 353:14-17.
5. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:88-96.
6. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007; 13:671-679.
7. Lonser RR, Glenn GM,Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet 2003; 361:2059-2067.
8. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90.
9. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004; 10:6290-6295.
10. Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561-566.
11. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
12. Li Y, Zhang T, Schwartz SJ, Sun D. New developments in HSP90 inhibitors as anti-cancer therapeutics: Mechanism, clinical perspective and more potential. Drug Resist Updat 2009; 12:17-27.
13. Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubésyndrome. Cancer Epidemiol Biomarkers Prev 2002; 11:393-400.
14. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177: 2074-2079.
15. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8:143-153.
16. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-478.
17. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
18. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
19. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178:1883-1887.
20. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
22. De Mulder PH, Riogas J, Gillessen S, Srinivas S, Pisa P, Vogelzang N, et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl):S223.
23. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008; 44:2152-2161.
24. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-1861.
25. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694.
26. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972.
27. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002; 40:580-581.
28. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512. (Pubitemid 46630627)
29. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
30. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280-1289.
31. Amato R, Harris JP, Dalton M, Khan M, Alter R, Zhai Q, et al. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell cancer (MRCC). J Clin Oncol 2007; 25 (Suppl):S18.
32. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25:3296-3301.
33. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25:3288-3295.
34. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet 2007; 8:975-984.
35. Rini B, Wilding GT, Hudes G, Stadler WM, Kim S, Tarazi JC, et al. Axitinib (AG-013736; AG) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 2007; 25 (Suppl):S18.
36. Hudson CC, Davis ID, Machiels JP, de Souza PL, Hong BF, Rottey S, et al. Pazopanib (GW786034) is active in metastatic renal cell cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007; 25 (Suppl): S18.
37. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
38. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
39. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111.
40. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-5428.
41. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-619.
42. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-348.
43. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66:5549-5554.
44. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25:3958-3964.
45. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
46. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115:2438-2446.
47. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
48. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J,Wong J, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004; 10:7812-7819.
49. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23:7889-7896.
50. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combinedwith bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536-4541.
51. Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008; 26:2285-2291.
52. Rathmell K, Amin C,Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). In: 2008 ASCO genitourinary cancers symposium [Abstract 370].
53. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26:3743-3748.
54. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27: 235-241.
55. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
56. Eder J, Heath E, Appleman L, Shapiro G,Wang D, Malburg L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients with solid tumors. J Clin Oncol 2007; 25 (Suppl):S18.
57. Ross RW, Stein M, Santopoulos J, Eisenberg P, Logan T, Srinivas S, et al. A phase II study of the c-MET RTK inhibitor XL880 in patients with papillary renal cell carcinoma(PRC). J Clin Oncol 2007; 25 (Suppl):S18.
58. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21:3133-3140.
59. Messing EM, Manola J,Wilding G, Propert K, Fleischmann J, Crawford ED, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21:1214-1222.